Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Precision Drilling
PDS
5
Lantheus
LNTH
US OptionsDetailed Quotes
CRDF250516C4000
- 0.05
- 0.000.00%
15min DelayClose May 9 15:59 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume717 Open Interest4.00Strike Price0.00Turnover264.31%IV52.26%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1331Delta0.2524Gamma53.20Leverage Ratio-0.0165Theta0.0000Rho7.08Eff Leverage0.0007Vega
Cardiff Oncology Newsroom
H.C. Wainwright Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $18
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $10
Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.
Cardiff Oncology Analyst Ratings
Express News | Cardiff Oncology, Inc. : H.c. Wainwright Raises Target Price to $18 From $17
Cardiff Oncology's Strategic Advances in Cancer Treatment: A Compelling Buy Opportunity
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Reports Q1 EPS (20c), Consensus (19c)
Cardiff Oncology | 8-K: Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Express News | Cardiff Oncology Q1 Income From Operations USD -14.382 Million Vs. IBES Estimate USD -13.5 Million
Express News | Cardiff Oncology Q1 Operating Expenses USD 14.491 Million
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Cardiff Oncology 1Q Loss/Shr 20c >CRDF
Cardiff Oncology | 10-Q: Quarterly report
William Blair Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Promising Developments in Cardiff Oncology's Cancer Treatment Boost Buy Rating
Cardiff Oncology Announces Second Patent for Onvansertib Combination
Express News | Cardiff Oncology Announces a Second Patent for the Treatment of Mcrc for Bev-Naïve Patients
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
